KBL IV today announced the completion of its merger with 180 Life Sciences , a clinical-stage biotechnology company focused on the development of drugs for treating inflammatory diseases, fibrosis and pain. This is KBL’s fourth successful SPAC.
Shares and warrants are expected to begin trading today on the Nasdaq under the ticker symbols “ATNF” and “ATNFW.” Read more.
